Unit of Orofacial Genetics, 1 Department of Paediatrics, School of Medicine, "Agia Sophia" Children's Hospital, National Kapodistrian University of Athens, Athens, Greece.
Department of Molecular Genetics, "Cephalogenetics" Center, Athens, Greece.
In Vivo. 2021 Jan-Feb;35(1):95-103. doi: 10.21873/invivo.12236.
Idiopathic pregnancy complications pose a major threat to both maternal and fetal health worldwide. Numerous studies have implicated the role of the renin-angiotensin system (RAS) in the development of obstetric syndromes, since it is crucial for the uteroplacental function. A major RAS component is the angiotensin-converting enzyme (ACE), which hydrolyses angiotensin I to angiotensin II, and not only regulates arterial pressure, but also fibrinolytic activity, indirectly, through the expression of plasminogen activator inhibitor-1. A key functional polymorphism of the ACE gene is the insertion/deletion (I/D) polymorphism, which affects gene expression and product levels, and can therefore lead to high blood pressure and/or reduced fibrinolytic activity. These can cause major pregnancy complications, such as preeclampsia, recurrent pregnancy loss and preterm birth. This review discusses how the ACE I/D is associated with susceptibility towards pregnancy complications, on its own or in combination with other functional gene polymorphisms such, as the angiotensin II receptor type 1 (AT1R) A1166CC, angiotensin II receptor type 2 (AT2R) G1332A, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, matrix metallopeptidase-9 (MMP-9) C1562T, angiotensinogen (AGT) M235T, renin (REN) 83A/G, factor XIII (F13) Val34Leu and endothelial nitric oxide synthase (eNOS) 4a/b.
特发性妊娠并发症对全球母婴健康构成重大威胁。大量研究表明,肾素-血管紧张素系统(RAS)在产科综合征的发展中起作用,因为它对胎盘功能至关重要。RAS 的一个主要组成部分是血管紧张素转换酶(ACE),它将血管紧张素 I 水解为血管紧张素 II,不仅通过纤溶酶原激活物抑制剂-1 的表达间接调节动脉血压,还调节纤溶活性。ACE 基因的一个关键功能多态性是插入/缺失(I/D)多态性,它影响基因表达和产物水平,因此可以导致高血压和/或纤溶活性降低。这些因素可能导致主要的妊娠并发症,如先兆子痫、复发性流产和早产。这篇综述讨论了 ACE I/D 如何与妊娠并发症的易感性相关,无论是单独存在还是与其他功能基因多态性(如血管紧张素 II 受体 1(AT1R)A1166CC、血管紧张素 II 受体 2(AT2R)G1332A、纤溶酶原激活物抑制剂-1(PAI-1)4G/5G、基质金属蛋白酶-9(MMP-9)C1562T、血管紧张素原(AGT)M235T、肾素(REN)83A/G、凝血因子 XIII(F13)Val34Leu 和内皮型一氧化氮合酶(eNOS)4a/b)相结合。